[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532264":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":13,"collaborators":7,"id":17,"slug":18,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":19,"sex":23,"minAge":24,"maxAge":25,"enrollmentInfo":26,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Sichuan Provincial People's Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","ceftazidime avibactam","Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \\> 50ml\u002Fmin was 2.5g (2g\u002F0.5g), once every 8 hours, and the infusion time was 2 hours.\n\nPatients with renal injury adjust the dosage according to eCrCL",{"type":14,"investigatorFullName":15,"investigatorTitle":16,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Lingai Pan","Associate Clinical Professor","100532264","precise-treatment-of-ceftazidime-avibactam-in-patients-with-cro-infections-under-the-guidance-of-tdm-and-ppk-model-100532264",false,"NCT06210542","Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model","Inclusion Criteria:\n\n1. 18-85 years old.\n2. Hospitalized participants in ICU who did not receive Ceftazidime Avibactam treatment within 15 days before joining the study.\n3. Participants with severe infection (refer to the 2022 sepsis3.0 guidelines for the definition of severe infection).\n4. at least one carbapenem-resistant Gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and \u002F or Pseudomonas aeruginosa) was confirmed by bacterial culture in the primary infection site samples.\n5. sufficient respiratory secretions, blood and peritoneal effusion can be obtained within 48 hours before the first administration for bacterial culture and drug sensitivity test.\n6. intravenous injection of Ceftazidime Avibactam for more than 72 hours.\n7. understand compliance with research procedures and methods, voluntarily participate in this study, and sign informed consent in writing.\n\nExclusion Criteria:\n\n1. Participants are less than 18.\n2. Death within 72 hours after the start of treatment.\n3. Known resistance to β-lactam antibacterial drugs including cephalosporins, cephalosporin compound preparations containing β-lactamase inhibitors, or Those with a history of allergies to ceftazidime avibactam sodium for injection and its excipients.\n4. No indication for treatment with ceftazidime avibactam.\n5. Pregnant and lactating women.","ALL","18 Years","85 Years",{"count":27,"type":28},50,"ESTIMATED","OBSERVATIONAL","The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and extracorporeal membrane oxygenation(ECMO) patients).",[32,33],"ECMO","Carbapenem-Resistant Enterobacteriaceae Infection","NOT_YET_RECRUITING","2024-01-14",{"date":37,"type":38},"2024-01-18","ACTUAL",{"date":40,"type":28},"2024-01",{"date":42,"type":28},"2026-12",{"name":5,"class":6}]